

## Special Issue

# Brain Tumor Diagnosis and Targeted Therapy

### Message from the Guest Editor

Despite our progress in the molecular understanding of brain tumor biology, translating these advances has remained a challenge in the field. As the brain tumor space keeps evolving to leverage new knowledge generated by cutting-edge technologies, including single-cell transcriptomics, advances in spatially resolved approaches, and innovations in nano-carriers and drug-delivery technology, we can expect to see creative solutions being developed to diagnose and treat brain tumors. This Special Issue aims to highlight forward thinking points of view on how to move the field forward as well as showcase innovative research approaches aimed at improving diagnosis and therapy for brain tumors.

---

### Guest Editor

Dr. Hernando Lopez-Bertoni

1. Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA
2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

---

### Deadline for manuscript submissions

closed (29 February 2024)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/181993](https://mdpi.com/si/181993)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).